Clement D L, De Buyzere M, Duprez D
University Hospital, Department of Cardiovascular Diseases, Ghent, Belgium.
Am J Hypertens. 1993 Mar;6(3 Pt 2):14S-19S. doi: 10.1093/ajh/6.3.14s.
Although left ventricular hypertrophy (LVH) is an adaptive response to the increased load imposed on the heart in patients with hypertension, it ultimately is itself a major risk factor for cardiovascular disease. The influence of LVH on left ventricular function and on the coronary circulation, and the occurrence of serious ventricular arrhythmias are the major mechanisms of this increased risk. There is no doubt that regression of LVH occurs, but there are clear differences in this respect among antihypertensive drugs: angiotensin-converting enzyme (ACE) inhibitors and calcium antagonists produce the best response. Whether regression of LVH also causes an improvement in left ventricular function is unclear; various studies using the same drugs have yielded contradictory results. Furthermore, it has yet to be determined whether regression of LVH has a positive influence on the long-term prognosis in such patients; the results of the European Multicenter Study OvA will help in shedding more light on this important question.
虽然左心室肥厚(LVH)是高血压患者心脏负荷增加时的一种适应性反应,但它本身最终是心血管疾病的一个主要危险因素。LVH对左心室功能和冠状动脉循环的影响以及严重室性心律失常的发生是这种风险增加的主要机制。毫无疑问,LVH会发生消退,但在这方面抗高血压药物之间存在明显差异:血管紧张素转换酶(ACE)抑制剂和钙拮抗剂产生的反应最佳。LVH的消退是否也会改善左心室功能尚不清楚;使用相同药物的各种研究得出了相互矛盾的结果。此外,LVH的消退对此类患者的长期预后是否有积极影响尚未确定;欧洲多中心研究OvA的结果将有助于更清楚地阐明这个重要问题。